AbbVie making progress with US FTC on Cerevel acquisition, AbbVie executive says
AbbVie's talks with the US Federal Trade Commission over its $8.7 billion acquisition of Cerevel Therapeutics are advancing well, the company’s chief operating officer told investors at a conference.AbbVie's talks with...To view the full article, register now.
Already a subscriber? Click here to view full article